Search

The current investigation focuses on developing multi-drug-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles clothed with leucocyte membrane. Firstly, Paclitaxel (PTX) and Cannabidiol (CBD) were encapsulated in PLGA vesicles which were further coated by a leucocytic membrane (LMc-PTX-CBD-NPs) for efficient targeting of the cancerous cells. Particle size of uncoated and coated nanoparticles was observed to be 149 and 171 nm with the zeta potential of −6 and −10.5 mv, respectively. Later, TEM analysis shows circular particle morphology along with uniform coating of membrane over prepared particles. The prepared formulation possesses prolonged release pattern as well as it shows no hemolytic toxicity. Cytotoxicity analysis in MCF-7 cells of LMc-PTX-CBD-NPs showed better potency than conventional formulation, thus more efficient in targeting cancerous cells. Additionally, greater inhibition of cell migration indicated an improved anti-metastatic effect. Additionally, higher proportion of nuclear fragmentation occurred due to which major changes in cell morphology were observed after treatment with LMc-PTX-CBD-NPs. Thus, prepared formulation could be an efficient approach for successful combination therapy with efficient targeting and reduced side effects to tackle breast cancer. [Display omitted] • We developed multi-drug-loaded PLGA nanoparticles clothed with leucocyte membrane. • Cytotoxicity in MCF-7 cells of LMc-PTX-CBD-NPs showed better potency. • Our formulation can be a good option in cancer therapy. [ABSTRACT FROM AUTHOR]

Targeted drug delivery has emerged as a pivotal approach within precision medicine, aiming to optimize therapeutic efficacy while minimizing systemic side effects. Leukocyte membrane coated nanoparticles (NPs) have attracted a lot of interest as an effective approach for delivering targeted drugs, capitalizing on the natural attributes of leukocytes to achieve site-specific accumulation, and heightened therapeutic outcomes. An overview of the present state of the targeted medication delivery research is given in this review. Notably, Leukocyte membrane-coated NPs offer inherent advantages such as immune evasion, extended circulation half-life, and precise homing to inflamed or diseased tissues through specific interactions with adhesion molecules. leukocyte membrane-coated NPs hold significant promise in advancing targeted drug delivery for precision medicine. As research progresses, they are anticipated to contribute to improved therapeutic outcomes, enabling personalized and effective treatments for a wide range of diseases and conditions. The review covers the method of preparation, characterization, and biological applications of leucocytic membrane coated NPs. Further, patents related factors, gap of translation from laboratory to clinic, and future prospective were discussed in detail. Overall, the review covers extensive literature to establish leucocytic membrane NPs for targeted drug delivery. [Display omitted] [ABSTRACT FROM AUTHOR]

[Display omitted] Non-melanoma skin cancer is one of the most common malignancies reported with high number of morbidities, demanding an advanced treatment option with superior chemotherapeutic effects. Due to high degree of drug resistance, conventional therapy fails to meet the desired therapeutic efficacy. To break the bottleneck, nanoparticles have been used as next generation vehicles that facilitate the efficient interaction with the cancer cells. Here, we developed combined therapy of 5-fluorouracil (5-FU) and cannabidiol (CBD)-loaded nanostructured lipid carrier gel (FU-CBD-NLCs gel). The NLCs were optimized using central composite design that showed an average particle size of 206 nm and a zeta potential of −34 mV. In addition, in vitro and ex vivo drug permeations studies demonstrated the effective delivery of both drugs in the skin layers via lipid structured nanocarriers. Also, the prepared FU-CBD-NLCs showed promising effect in-vitro cell studies including MTT assays, wound healing and cell cycle as compared to the conventional formulation. Moreover, dermatokinetic studies shows there was superior deposition of drugs at epidermal and the dermal layer when treated with FU-CBD-NLCs. In the end, overall study offered a novel combinatorial chemotherapy that could be an option for the treatment of non-melanoma skin cancer. [ABSTRACT FROM AUTHOR]